KRAS mutation analysis of single circulating tumor cells from patients with metastatic colorectal cancer

BMC Cancer

Research Article

Yuurin Kondo¹  Kazuhiko Hayashi¹  Kazuyuki Kawakami¹  Masakazu Yamamoto²  Yukari Miwa³  Hiroshi Hayashi³ 

[1] Department of Chemotherapy and Palliative Care, Tokyo Women’s Medical University, 8-1 Kawada-chyo, Shinjuku-ku, 162-8666, Tokyo, Japan;Department of Surgery, Institute of Gastroenterology, Tokyo Women’s Medical University, Shinjuku, Japan;Research & Development Department, SRL, Inc., Shinjuku, Japan;

关键词: Circulating tumor cells;    Mutation analysis;    KRAS;    Single cell analysis;    Heterogeneity;   

DOI  :  10.1186/s12885-017-3305-6

 received in 2016-03-02, accepted in 2017-04-25,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundThe molecular profiles of tumors may inform the selection of appropriate targeted therapies. Circulating tumor cells (CTCs) reflect the real-time status of tumor genotypes. CTCs exhibit high genetic heterogeneity within a patient; accordingly, the analysis of individual CTCs, including their heterogeneity, may enable more precise treatments. We analyzed KRAS mutations in single CTCs from patients with metastatic colorectal cancer (mCRC) using a new single-cell picking system.MethodsBlood samples were obtained from 61 patients with mCRC. CTCs were enriched and fluorescently labeled using the CellSearch® System. They were recovered using the single-cell picking system based on the fluorescence intensity of marker dyes. Single CTCs and tumor tissue samples were examined for mutations in codons 12 and 13 of the KRAS gene.ResultsCTCs were detected in 27 of 61 patients with mCRC. We isolated at least two CTCs from 15 of 27 patients. KRAS genotype was evaluated in a total of 284 CTCs from 11 patients, and 15 cells with mutations were identified in four patients. In 10 of 11 patients, the KRAS status was the same in the primary tumor and CTCs. In one patient, the KRAS status was discordant between the primary tumor and CTCs. In two patients, different KRAS mutations were found among individual CTCs.ConclusionsWe successfully isolated single CTCs and detected KRAS mutations in individual cells from clinical samples using a novel application of single-cell isolation system. Using the system, we detected CTC heterozygosity and heterogeneity in KRAS status among CTCs within a patient and between CTCs and tumor tissues.

【 授权许可】

CC BY   
© The Author(s). 2017